Pulmonary Medicine: A subspecialty of internal medicine concerned with the study of the RESPIRATORY SYSTEM. It is especially concerned with diagnosis and treatment of diseases and defects of the lungs and bronchial tree.Lung Diseases: Pathological processes involving any part of the LUNG.Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.Hypertension, Renal: Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN.Hypertension, Portal: Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.Blood Pressure: PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS.Hypertension, Renovascular: Hypertension due to RENAL ARTERY OBSTRUCTION or compression.Antihypertensive Agents: Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.Pulmonary Artery: The short wide vessel arising from the conus arteriosus of the right ventricle and conveying unaerated blood to the lungs.Bone Morphogenetic Protein Receptors, Type II: A subtype of bone morphogenetic protein receptors with low affinity for BONE MORPHOGENETIC PROTEINS. They are constitutively active PROTEIN-SERINE-THREONINE KINASES that can interact with and phosphorylate TYPE I BONE MORPHOGENETIC PROTEIN RECEPTORS.ChicagoMonocrotaline: A pyrrolizidine alkaloid and a toxic plant constituent that poisons livestock and humans through the ingestion of contaminated grains and other foods. The alkaloid causes pulmonary artery hypertension, right ventricular hypertrophy, and pathological changes in the pulmonary vasculature. Significant attenuation of the cardiopulmonary changes are noted after oral magnesium treatment.Dendrobium: A plant genus of the family ORCHIDACEAE that contains dihydroayapin (COUMARINS) and phenanthraquinones.Newspapers: Publications printed and distributed daily, weekly, or at some other regular and usually short interval, containing news, articles of opinion (as editorials and letters), features, advertising, and announcements of current interest. (Webster's 3d ed)Heart Murmurs: Heart sounds caused by vibrations resulting from the flow of blood through the heart. Heart murmurs can be examined by HEART AUSCULTATION, and analyzed by their intensity (6 grades), duration, timing (systolic, diastolic, or continuous), location, transmission, and quality (musical, vibratory, blowing, etc).Vectorcardiography: Recording of the moment-to-moment electromotive forces of the heart on a plane of the body surface delineated as a vector function of time.Heart Sounds: The sounds heard over the cardiac region produced by the functioning of the heart. There are four distinct sounds: the first occurs at the beginning of SYSTOLE and is heard as a "lubb" sound; the second is produced by the closing of the AORTIC VALVE and PULMONARY VALVE and is heard as a "dupp" sound; the third is produced by vibrations of the ventricular walls when suddenly distended by the rush of blood from the HEART ATRIA; and the fourth is produced by atrial contraction and ventricular filling.Heart Auscultation: Act of listening for sounds within the heart.Phonocardiography: Graphic registration of the heart sounds picked up as vibrations and transformed by a piezoelectric crystal microphone into a varying electrical output according to the stresses imposed by the sound waves. The electrical output is amplified by a stethograph amplifier and recorded by a device incorporated into the electrocardiograph or by a multichannel recording machine.Radiography, Thoracic: X-ray visualization of the chest and organs of the thoracic cavity. It is not restricted to visualization of the lungs.Marketing: Activity involved in transfer of goods from producer to consumer or in the exchange of services.Research Report: Detailed account or statement or formal record of data resulting from empirical inquiry.Accreditation: Certification as complying with a standard set by non-governmental organizations, applied for by institutions, programs, and facilities on a voluntary basis.Joint Commission on Accreditation of Healthcare Organizations: A private, voluntary, not-for-profit organization which establishes standards for the operation of health facilities and services, conducts surveys, and awards accreditation.IllinoisSoftware: Sequential operating programs and data which instruct the functioning of a digital computer.Kidney Transplantation: The transference of a kidney from one human or animal to another.Emergency Shelter: Temporary shelter provided in response to a major disaster or emergency.Nitric Oxide: A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP.Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.Endothelium, Vascular: Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components.Still's Disease, Adult-Onset: Systemic-onset rheumatoid arthritis in adults. It differs from classical rheumatoid arthritis in that it is more often marked by acute febrile onset, and generalized lymphadenopathy and hepatosplenomegaly are more prominent.HLA-B39 Antigen: A specific HLA-B surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-B*39 allele family.Arthritis, Juvenile: Arthritis of children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.Interleukin-18: A cytokine which resembles IL-1 structurally and IL-12 functionally. It enhances the cytotoxic activity of NK CELLS and CYTOTOXIC T-LYMPHOCYTES, and appears to play a role both as neuroimmunomodulator and in the induction of mucosal immunity.Prostaglandins I: A class of cyclic prostaglandins that contain the 6,9-epoxy bond. Endogenous members of this family are biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES.Hypertrophy, Right Ventricular: Enlargement of the RIGHT VENTRICLE of the heart. This increase in ventricular mass is often attributed to PULMONARY HYPERTENSION and is a contributor to cardiovascular morbidity and mortality.Bronchopulmonary Dysplasia: A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.Surface-Active Agents: Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics.Phosphodiesterase 5 Inhibitors: Compounds that specifically inhibit PHOSPHODIESTERASE 5.Pyrazoles: Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.Pyrimidines: A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.Guanylate Cyclase: An enzyme that catalyzes the conversion of GTP to 3',5'-cyclic GMP and pyrophosphate. It also acts on ITP and dGTP. (From Enzyme Nomenclature, 1992) EC 4.6.1.2.ArchivesAwareness: The act of "taking account" of an object or state of affairs. It does not imply assessment of, nor attention to the qualities or nature of the object.Fees, Pharmaceutical: Amounts charged to the patient or third-party payer for medication. It includes the pharmacist's professional fee and cost of ingredients, containers, etc.Copyright: It is a form of protection provided by law. In the United States this protection is granted to authors of original works of authorship, including literary, dramatic, musical, artistic, and certain other intellectual works. This protection is available to both published and unpublished works. (from Circular of the United States Copyright Office, 6/30/2008)BooksComplement C3d: A 302-amino-acid fragment in the alpha chain (672-1663) of C3b. It is generated when C3b is inactivated (iC3b) and its alpha chain is cleaved by COMPLEMENT FACTOR I into C3c, and C3dg (955-1303) in the presence COMPLEMENT FACTOR H. Serum proteases further degrade C3dg into C3d (1002-1303) and C3g (955-1001).Epoprostenol: A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY).Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.Iloprost: An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Stroke Volume: The amount of BLOOD pumped out of the HEART per beat, not to be confused with cardiac output (volume/time). It is calculated as the difference between the end-diastolic volume and the end-systolic volume.
"Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension". New England Journal of Medicine. 335 (9): 609-16. ... Epidemics of fatal pulmonary hypertension and heart valve damage associated with pharmaceutical anorectic agents have led to ... "Journal of Natural Science, Biology and Medicine. 5 (2): 340-4. doi:10.4103/0976-9668.136180. PMC 4121911. PMID 25097411.. ... Many amphetamines produce side effects, including addiction, tachycardia and hypertension,[4] making prolonged unsupervised use ...
Fowler, Robin (2012). "Exercise Intolerance in Pulmonary Arterial Hypertension". Pulmonary Medicine. June: 359204. doi:10.1155/ ... Cardiac arrhythmia Aortic valve insufficiency Pulmonary artery hypertension: PAH has the following symptoms; dyspnea and ... 110 mm Hg Severe pulmonary hypertension Severe chronic fatigue syndrome Suspected or known dissecting aortic aneurysm Recent ... Dysfunctions involving the pulmonary, cardiovascular or neuromuscular systems have been frequently found to be associated with ...
"Risk factors for pulmonary arterial hypertension". Clinics in chest medicine. 22 (3): 459-475. doi:10.1016/S0272-5231(05)70284- ... Symptoms appeared as a typical pneumonia with interstitial infiltrates on chest X-ray, complicated by pulmonary hypertension in ...
"Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension". Nature Medicine. 8 (10): 1129-35. doi: ... This article incorporates text from the United States National Library of Medicine, which is in the public domain.. ... Roth BL (Jan 2007). "Drugs and valvular heart disease". The New England Journal of Medicine. 356 (1): 6-9. doi:10.1056/ ... The 5-HT2B receptor subtype is involved in: CNS: presynaptic inhibition, behavioural effects Vascular: pulmonary ...
"Inhaled Iloprost for Severe Pulmonary Hypertension". New England Journal of Medicine. 347 (5): 322-329. doi:10.1056/ ... This may be a sign of pulmonary venous hypertension. Pulmonary arterial hypertension (PAH) Raynaud's phenomenon Scleroderma " ... Should signs of pulmonary edema occur when inhaled iloprost is administered in patients with pulmonary hypertension, the ... Iloprost should be stopped immediately if signs of pulmonary edema occur. This may be a sign of pulmonary venous hypertension. ...
... is also used in high-altitude medicine to treat high altitude pulmonary edema. Other uses include painful spasms of ... It is also used for the small subset of people with pulmonary hypertension. Nifedipine rapidly lowers blood pressure, and ... Hypertension: management of hypertension in adults in primary care. Clinical guideline CG34. National Institute for Health and ... It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health ...
"Treatment of Pulmonary Arterial Hypertension". The New England Journal of Medicine. 351: 1425-1436. doi:10.1056/NEJMra040291. " ... Pulmonary hypertension (PAH) is disease of small pulmonary arteries that is usually caused by more than one mechanism. This ... Complications in this response arise in acute coronary syndromes and pulmonary arterial hypertension. These complications lead ... there are no current cures for pulmonary arterial hypertension, but there are treatment options for patients with the disease ...
"Adempas not for use in patients with pulmonary hypertension caused by idiopathic interstitial pneumonia". European Medicines ... chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Riociguat constitutes the ... "Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension". New England Journal of Medicine. 369 (4): 319- ... The Pulmonary Arterial Hypertension sGC-Stimulator Trial (PATENT) was a randomized, placebo-controlled trial that investigated ...
"Efficacy and Safety of Sildenafil Treatment in Pulmonary Arterial Hypertension: a Systematic Review". Respiratory Medicine. 108 ... Pulmonary hypertension. While sildenafil improves some markers of disease in people with pulmonary arterial hypertension, it ... Sildenafil is available as a generic drug in the United States, labelled for pulmonary arterial hypertension.[77] As of 2016[ ... In Canada, Pfizer's patent 2,324,324 for Revatio (sildenafil used to treat pulmonary hypertension) was found invalid by the ...
Patients with coronary artery disease or pulmonary hypertension will take additional medicines described by their physician. ... Pulmonary artery enlargement: the test will help to determine if there is a large volume of blood in the pulmonary veins and ... Loud mitral S1 and wide fixed split of pulmonary S2: The loud sound of the mitral S1 and the wide fixed split of pulmonary S2 ... pulmonary vascular congestion, marked left atrial enlargement: the test will help to determine if there is a sign of MS and ...
"Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension: A Network Meta-Analysis". Medicine ... IP receptor agonists are front-line drugs to treat pulmonary hypertension. Major drugs in this category include PGI2 itself (i. ... Sitbon O, Vonk Noordegraaf A (January 2017). "Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience ... This article incorporates text from the United States National Library of Medicine, which is in the public domain. ...
... and European Medicines Agency, and designated an orphan drug, for the treatment of pulmonary hypertension. Ambrisentan is ... "Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension". New England Journal of Medicine. 373 (9): 834-44 ... "FDA Approves New Orphan Drug for Treatment of Pulmonary Arterial Hypertension" (Press release). Food and Drug Administration. ... "U.S. Food and Drug Administration Approves Gilead's Letairis Treatment of Pulmonary Arterial Hypertension" (Press release). ...
Harrison "Hap" Farber is Professor of Medicine and Director of the Pulmonary Hypertension Center at Boston University. He ... Farber is a Professor in the Department of Medicine and attends in the Medical Intensive Care Unit and on the Pulmonary ... He completed a fellowship in pulmonary and critical care medicine at Boston University and Boston City Hospital Program. Dr. ... He also oversees the care of all patients with Pulmonary Hypertension at Boston Medical Center. Dr. Farber's research focuses ...
The marketed medicines are Remodulin, Tyvaso, Orenitram and Adcirca for pulmonary arterial hypertension, and Unituxin for ... Clinical trials of new medicines related to pulmonary hypertension include INCREASE for interstitial lung disease, SOUTHPAW for ... "United Therapeutics and DEKA Sign Agreement for New PAH Remodulin Delivery System". Pulmonary Hypertension News. January 2, ... In 1994, Rothblatt's young daughter was diagnosed with a fatal orphan disease, pulmonary arterial hypertension (PAH). Rothblatt ...
... and endowed the Chair in Pulmonary Arterial Hypertension at the David Geffen School of Medicine at UCLA. In 2008, Brandman ...
Various medicines and therapies for pulmonary hypertension are under investigation for treatment of the symptoms. Eisenmenger ... After pulmonary hypertension is sufficient to reverse the blood flow through the defect, however, the maladaptation is ... Wood, P (1958). "Pulmonary hypertension with special reference to the vasoconstrictive factor". British heart journal. 20 (4): ... If the inciting defect in the heart is identified before it causes significant pulmonary hypertension, it can normally be ...
"Efficacy and Safety of Sildenafil Treatment in Pulmonary Arterial Hypertension: a Systematic Review". Respiratory Medicine. 108 ... While sildenafil improves some markers of disease in people with pulmonary arterial hypertension, it does not appear to affect ... Sildenafil is available as a generic drug in the United States, labelled for pulmonary arterial hypertension. As of 2016[update ... In Canada, Pfizer's patent 2,324,324 for Revatio (sildenafil used to treat pulmonary hypertension) was found invalid by the ...
"Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension: A Network Meta-Analysis". Medicine ... IP receptor agonists are front-line drugs to treat pulmonary hypertension. Major drugs in this category include PGI2 itself (i. ... Sitbon O, Vonk Noordegraaf A (January 2017). "Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience ... "A Comparison of Inhaled Nitric Oxide Versus Inhaled Epoprostenol for Acute Pulmonary Hypertension Following Cardiac Surgery". ...
"Pulmonary arterial hypertension associated with congenital heart disease". Clinics in chest medicine. 34 (4): 707-17. doi: ... This switch in blood flow direction is precipitated by pulmonary hypertension due to increased pulmonary blood flow in a left- ... The right ventricle hypertrophies to compensate for this pulmonary hypertension, so the right ventricular pressure becomes ... Pulmonary stenosis (narrowing of the pulmonary valve and outflow tract, obstructing blood flow from the right ventricle to the ...
The New England Journal of Medicine. 306 (10): 557-64. doi:10.1056/NEJM198203113061001. PMID 6799824. Pulmonary Hypertension: A ... Pulmonary Hypertension: A Patient's Survival Guide 3rd ed. p.134. Pulmonary Hypertension: A Patient's Survival Guide 3rd ed. p ... idiopathic pulmonary fibrosis; 14% cystic fibrosis; 12% idiopathic (formerly known as "primary") pulmonary hypertension; 5% ... Bruce Reitz of Stanford University in 1981 on a woman who had idiopathic pulmonary hypertension. 1983: First successful long- ...
2004). "Sitaxsentan therapy for pulmonary arterial hypertension". American Journal of Respiratory and Critical Care Medicine. ... Sitaxentan sodium (TBC-11251) is a medication for the treatment of pulmonary arterial hypertension (PAH). It was marketed as ... "Encysive Pharmaceuticals to Conduct Phase III Study With Thelin (Sitaxsentan Sodium) in Pulmonary Arterial Hypertension". ... 2007). "Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with ...
Richalet, Jean-Paul (2005): Sildenafil Inhibits Altitude-induced Hypoxemia and Pulmonary Hypertension. I: American Journal of ... Respiratory and Critical Care Medicine, 171 (3): 275-281. *^ European Medicines Agency. Science Medicines Health: Bilag 1 - ... Pulmonal arteriel hypertension og lungefibrose[redigér , redigér wikikode]. Pulmonal arteriel hypertension er for højt blodtryk ... Ghofrani, Hossein Ardeschir (2002): Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised ...
It can be associated with pulmonary hypertension. Because of this, the condition is also widely known as Persistent Pulmonary ... In many countries patients must bring their own supplies, even acquire their own medicines, before treatment can be given." The ... Persistent fetal circulation (also called Persistent Pulmonary Hypertension of the Newborn, PPHN) is a condition caused by a ... Graves ED, Redmond CR, Arensman RM (March 1988). "Persistent pulmonary hypertension in the neonate". Chest. 93 (3): 638-41. doi ...
Mutations in TOPBP1 cause Idiopathic pulmonary arterial hypertension . GRCh38: Ensembl release 89: ENSG00000163781 - Ensembl, ... American Journal of Respiratory and Critical Care Medicine. 189 (10): 1260-72. doi:10.1164/rccm.201310-1749OC. PMID 24702692. ... "Whole-exome sequencing reveals TopBP1 as a novel gene in idiopathic pulmonary arterial hypertension". ...
Advances in the Management of Pulmonary Arterial Hypertension (Future Medicine, London, UK. 2013); and Lung Stem Cells in the ... for Scholarly Activities of the Department of Medicine at the College of Medicine and Director of the Program in Pulmonary ... Yuan began his academic career as a Research Assistant Professor of Medicine at the University of Maryland School of Medicine ( ... an American physician scientist whose research interests center on pulmonary vascular pathobiology and pulmonary hypertension. ...
a b MedlinePlus Medical Encyclopedia: Nosebleed U.S. National Library of Medicine Medline Plus service. Retrieved 2010-03-15. ... due to general hypertension) tends to increase the duration of spontaneous epistaxis.[7] Anticoagulant medication and disorders ... British journal of hospital medicine (London, England : 2005). 75 (3): 143-7. doi:10.12968/hmed.2014.75.3.143. PMID 24621629.. ... "Is epistaxis evidence of end-organ damage in patients with hypertension?". Laryngoscope. 109 (7): 1111-1115. doi:10.1097/ ...
Pulmonary arterial hypertension (PAH) occurring in AOSD is rarely described in literature. We present the case of a young ... From: Pulmonary arterial hypertension in adult onset Stills disease: a case report of a severe complication ...
Its a rare lung disorder in which the blood vessels in the lungs narrow and the pressure in the pulmonary artery rises far ... Primary pulmonary hypertension (PPH) is high blood pressure in the lungs. ... Pulmonary Lung and Respiratory System What is primary pulmonary hypertension?. Primary pulmonary hypertension (PPH) is high ... Key points about pulmonary hypertension. *Primary pulmonary hypertension (PPH) is a rare lung disorder that causes high blood ...
What is persistent pulmonary hypertension?. In persistent pulmonary hypertension, also known as persistent fetal circulation, a ... Blood Test Shows Promise In Gauging Severity Of Pulmonary Arterial Hypertension. *Drug Now In Clinical Trials For Parkinsons ...
Setting out to determine the survival of patients with pulmonary arterial hypertension (PAH), researchers at the University of ... Associate Professor of Medicine and Director of Pulmonary Hypertension at the University of Chicago Medical Center. Our ... Researchers revisit pulmonary arterial hypertension survival. Survival improves but prognostication tool sorely outdated. ... Setting out to determine the survival of patients with pulmonary arterial hypertension (PAH), researchers at the University of ...
Professor of Medicine. Pulmonary and Critical Care Medicine. Director, Pulmonary Hypertension Program. Johns Hopkins Medicine ... Associate Professor of Medicine. Pulmonary and Critical Care Medicine. Director, Adult Pulmonary Hypertension Program. Stanford ... Associate Professor of Medicine. Pulmonary and Critical Care Medicine. Director, Adult Pulmonary Hypertension Program. Stanford ... Ford Investigator of Pulmonary Medicine. Director of Pulmonary Research. Co-director, Pulmonary Hypertension Program. Indiana ...
BMJ Evidence-Based Medicine Jun 2013, 18 (3) e26; DOI: 10.1136/eb-2012-100971 ... BMJ Evidence-Based Medicine Feb 2013, 18 (1) 37-38; DOI: 10.1136/ebmed-2012-100651 ... BMJ Evidence-Based Medicine Oct 2008, 13 (5) 154; DOI: 10.1136/ebm.13.5.154 ... BMJ Evidence-Based Medicine Aug 2007, 12 (4) 125; DOI: 10.1136/ebm.12.4.125 ...
Medicine Market Professional Survey Report 2016 to their offerings. ... ReportBazzar has included a new report titled Global Pulmonary Arterial Hypertension (PAH) ... Global Pulmonary Arterial Hypertension (PAH) Medicine Market Professional Survey Report 2016. Thursday, August 25, 2016 General ...
NHLBI grants will fund use of iPS cells to study insulin resistance and pulmonary hypertension Two School of Medicine research ... Pulmonary hypertension, a deadly form of high blood pressure that develops in the lungs, may be caused by an inflammation- ... Pulmonary hypertension, while rare, usually strikes young and middle-aged women, leaving them short of breath and often unable ... About 100,000 people in the United States and Europe have been diagnosed with pulmonary hypertension, but many others are ...
Phentolamine for Primary Pulmonary Hypertension SE DO CHA, M.D.; MICHAEL KIRSCHBAUM, D.O.; VLADIR MARANHAO, M.D.; EMMONS PAINE ... To the editor: In the May issue, Ruskin and Hutter (1) reported a case of primary pulmonary hypertension in a patient who ... Phentolamine for Primary Pulmonary Hypertension. Ann Intern Med. 1979;91:927-928. doi: 10.7326/0003-4819-91-6-927_2 ...
PPARγ Activation: A Potential Treatment For Pulmonary Hypertension Message Subject. (Your Name) has forwarded a page to you ... Citation: G. Hansmann, R. T. Zamanian, PPARγ activation: A potential treatment for pulmonary hypertension. Sci. Transl. Med. 1 ... The pathobiology of pulmonary arterial hypertension (PAH) involves multiple molecular pathways and environmental modifiers and ... 3Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, CA, USA. ...
Vasodilator-Responsive Idiopathic Pulmonary Arterial Hypertension: Evidence for a New Disease? Annals of Internal Medicine; 162 ... Primary Pulmonary Hypertension and Oral Phentolamine Annals of Internal Medicine; 91 (3): 495-496 ... Adverse Hemodynamic Effects of Phentolamine in Primary Pulmonary Hypertension Annals of Internal Medicine; 95 (5): 591-592 ... Primary Pulmonary Hypertension Treated with Oral Phentolamine JEREMY N. RUSKIN, M.D.; ADOLPH M. HUTTER Jr., M.D. ...
Pulmonary hypertension. Pulmonary hypertension is high blood pressure in the arteries of your lungs. It happens when the lungs ... Pulmonary hypertension in advanced chronic obstructive pulmonary disease. Curr Opin Pulm Med . 2012;18(2):138-43. ... Pulmonary hypertension and right ventricular failure. Part VI. Classification and pathomorphology of primary pulmonary arterial ... Bech-Hanssen O, Karason K, Rundqvist B, Bollano E, Lindgren F, Selimovic N. Can pulmonary hypertension and increased pulmonary ...
Medicine Revenue, means the sales value of Pulmonary Arterial Hypertension (PAH) Medicine This report studies Pulmonary ... Arterial Hypertension (PAH) Medicine in Global market, especially in North America, Europe, China, Japan, Southeast Asia and ... means the output of Pulmonary Arterial Hypertension (PAH) ... 1.2 Pulmonary Arterial Hypertension (PAH) Medicine Segment by ... 1.3 Pulmonary Arterial Hypertension (PAH) Medicine Segment by Application. 1.3.1 Pulmonary Arterial Hypertension (PAH) Medicine ...
Chloroquine in Pulmonary Arterial HypertensionA New Role for an Old Drug? John J. Ryan ... BMPR2 Mutations Influence Phenotype More Obviously in Male Patients With Pulmonary Arterial HypertensionClinical Perspective ... Osteoprotegerin Disruption Attenuates HySu-Induced Pulmonary Hypertension Through Integrin αvβ3/FAK/AKT Pathway Suppression ... α1-A680T Variant in GUCY1A3 as a Candidate Conferring Protection From Pulmonary Hypertension Among Kyrgyz HighlandersCLINICAL ...
2Department of Medicine, Imperial College London, London W12 0NN, UK.. *. 3National Pulmonary Hypertension Service, Imperial ... Research ArticlePulmonary Arterial Hypertension. Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial ... National Pulmonary Hypertension Service, Imperial College Healthcare National Health Service Trust, Hammersmith Hospital, Du ... National Pulmonary Hypertension Service, Imperial College Healthcare National Health Service Trust, Hammersmith Hospital, Du ...
... is the first Comprehensive Pulmonary Hypertension Care Center in Illinois to be recognized by the Pulmonary Hypertension ... nursing manager for the Pulmonary Hypertension Center. Accreditation as a Comprehensive Pulmonary Hypertension Care Center ... The University of Chicago Medicine is the first Comprehensive Pulmonary Hypertension Care Center in Illinois to be recognized ... associate professor of medicine, director of Pulmonary Hypertension Center and medical director of the lung transplant program ...
... our Advanced Heart Failure and Pulmonary Hypertension Program. ... The University of Chicago Medicine is now home to the Midwests ... Why Choose UChicago Medicine for Pulmonary Hypertension. Evaluating and treating pulmonary hypertension (PH) can be very ... Diagnosing & Treating Pulmonary Hypertension. Detecting Pulmonary Hypertension Your doctor may suspect that you have PH based ... Idiopathic and familial pulmonary arterial hypertension, formerly known as primary pulmonary hypertension, which is a rare ...
Therapeutic targets in neonatal pulmonary hypertension: Linking pathophysiology to clinical medicine. Publication. Publication ... Therapeutic targets in neonatal pulmonary hypertension: Linking pathophysiology to clinical medicine. Expert Review of ... Endothelin, Neonates, Nitric oxide, Pharmacotherapy, Phosphodiesterase, Prostaglandin, Pulmonary hypertension Persistent URL. ... Treatment of pulmonary hypertension in neonates is a major challenge on the intensive care unit and involves high morbidity and ...
... responsible for the protection of public and animal health through the scientific evaluation and supervision of medicines. ... Pulmonary arterial hypertension (PAH), revised WHO classification on pulmonary hypertension. Description. This document ... Clinical investigation of medicinal products for the treatment of pulmonary arterial hypertension. * Email ... Data on medicines (ISO IDMP standards)*SPOR master data*Referentials and organisations ...
... exercise pulmonary hypertension, sickle cell disease and pulmonary hypertension, and sarcoid pulmonary hypertension, among many ... This book provides a deep dive into the diagnosis and therapeutics of pulmonary hypertension supported by the literature and ... and other specialty practitioners caring for patients with pulmonary hypertension. ... review of recent guidelines and their applicability to the multiple different nuanced presentations of pulmonary hypertension. ...
... is a rare disease characterized by distinctive changes in pulmonary arterioles that lead to progressive pulmonary arterial ... many of which are highly expressed in developing heart and pulmonary vasculature. In the cohort of PAH without CHD, rare ... Pulmonary arterial hypertension (PAH) is a rare disease characterized by distinctive changes in pulmonary arterioles that lead ... Pulmonary arterial hypertension (PAH[MIM:178600]) is a rare disease characterized by distinctive changes in pulmonary ...
Pulmonary hypertension is heterogeneous from a pathophysiological point of view, and the diversity is reflected in the ... The different haemodynamic forms of pulmonary hypertension can be found in multiple clinical conditions which have been ... In fact, while transthoracic echocardiography may provide clues on the presence of pulmonary hypertension, the haemodynamic ... The presence of pulmonary hypertension, as defined above, is always an ominous prognostic sign, even if the severity may differ ...
Northwestern Medicine Bluhm Cardiovascular Institute is a nationally recognized destination for those who require highly ... Meet the Downtown Chicago Pulmonary Hypertension Team. Northwestern Medicine Bluhm Cardiovascular Institute is a nationally ... 2019 by Northwestern Medicine® and Northwestern Memorial HealthCare.. Northwestern Medicine® is a trademark of Northwestern ... Choose dates and times from several of our Family Medicine, Internal Medicine and Pediatric doctors. ...
... for Pulmonary Physician specializing in Lung Transplantation and Pulmonary Hypertension in the Division of Pulmonary Medicine. ... The University of Alberta, Faculty of Medicine & Dentistry, Department of Medicine, Division of Pulmonary Medicine in ... Pulmonary Hypertension and Interventional Pulmonary Medicine.. Division members also care for the second largest Lung ... www.ualberta.ca/department-of-medicine/divisions/pulmonary-medicine/publications).. The successful candidate will be an MD (or ...
From the Department of Cardiology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. ... 7 idiopathic pulmonary hypertension and 2 congenital heart disease) or bosentan (5/14, 4 idiopathic pulmonary hypertension and ... Alteration of pulmonary artery integrin levels in chronic hypoxia and monocrotaline-induced pulmonary hypertension. J Vasc Res ... Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary ...
  • Dilated RA/RV and she had HRCT and opinion is severe thoracic scoliosis with secondary lumber curve, pulmonary artery hypertension with bilateral perihilar interstitial edema cardiomegaly and current medicine used is Clopidogrel and Asprin, Digoxin, Bosentan, Ramipril ACE, Furosemide, Budesonide, Salbutamol, etc., but her recovery is nil. (icliniq.com)
  • Right Heart Catheterization - Or pulmonary artery catheterization is a test used to see how well your heart is pumping (how much it pumps per minute) and to measure the blood pressure in your heart and the main blood vessels in your lungs. (bch.org)
  • Pharmacological activation of the transcription factor PPARγ affects the expression of key genes involved in the development of pulmonary hypertension (PH), subsequently has a variety of beneficial effects in the vasculature, and hence might be a powerful treatment of PH. (sciencemag.org)
  • The ability of the RV to adapt to increased vascular resistance is influenced by several factors, including age and the rapidity of the development of pulmonary hypertension. (mhmedical.com)
  • Scientists at the Max Planck Institute for Heart and Lung Research in Bad Nauheim and Giessen University have discovered that transcription factor FoxO1 regulates the division of cells and plays a key role in the development of pulmonary hypertension. (eurekalert.org)
  • Reduced FoxO1 activity is therefore an important factor in the development of pulmonary hypertension. (eurekalert.org)
  • About 100,000 people in the United States and Europe have been diagnosed with pulmonary hypertension, but many others are believed to go undiagnosed because the main symptom, shortness of breath, is nonspecific. (stanford.edu)
  • The most common symptom of pulmonary hypertension is shortness of breath, first when you exercise and later while at rest. (stlukes-stl.com)
  • State-of-the-art treatment for this uncommon, but potentially fatal condition is available at only a few centers in the nation, including UChicago Medicine. (uchicagomedicine.org)
  • Thank you for your interest in spreading the word about Science Translational Medicine. (sciencemag.org)
  • Message Body (Your Name) thought you would like to see this page from the Science Translational Medicine web site. (sciencemag.org)